Birk Poller

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Top Venues

Drug metabolism and disposition: the biological fate of chemicals

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Markus Trunzer, Joana Teigão, Felix Huth, Birk Poller, Sandrine Desrayaud, Raquel Rodríguez-Pérez, Bernard Faller
Improving In Vitro-In Vivo Extrapolation (IVIVE) of Clearance Using Rat Liver Microsomes for Highly Plasma Protein Bound Molecules . Drug metabolism and disposition: the biological fate of chemicals (2024)
Markus Trunzer, Joana Teigão, Felix Huth, Birk Poller, Sandrine Desrayaud, Raquel Rodríguez-Pérez, Bernard Faller
Improving In Vitro-In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound Molecules. Drug metabolism and disposition: the biological fate of chemicals 52 (5) (2024)
Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H Markus Weiss, Heike Otto, Martin Fink, Till A Röhn
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and translational science 17 (2) (2024)
Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H Markus Weiss, Heike Otto, Martin Fink, Till A Röhn
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and translational science 17 (2) (2024)
Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H Markus Weiss, Heike Otto, Martin Fink, Till A Röhn
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and translational science 17 (2) (2024)
Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H Markus Weiss, Heike Otto, Martin Fink, Till A Röhn
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial. Clinical and translational science 17 (2) (2024)
Markus Trunzer, Joana Teigão, Felix Huth, Birk Poller, Sandrine Desrayaud, Raquel Rodríguez-Pérez, Bernard Faller
Improving In Vitro-In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound Molecules. Drug metabolism and disposition: the biological fate of chemicals 52 (5) (2024)
Alexander David James, Kenneth Kulmatycki, Birk Poller, Andrea A Romeo, Jan Jaap Van Lier, Kai Klein, David Pearson
Absorption, distribution, metabolism, and excretion of [ 14 C]iptacopan in healthy male volunteers and in in vivo and in vitro studies. Drug metabolism and disposition: the biological fate of chemicals (2023)
Birk Poller, David Pearson, Luc Alexis Leuthold, Martin Fink, Astrid Jullion, Patrick Schweigler, Ester Tor Carreras, Cyrille Marvalin, Christian Loesche, H Markus Weiss
Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug Disposition. Drug metabolism and disposition: the biological fate of chemicals 50 (12) (2022)
H Markus Weiss, Thomas Langenickel, Meredith Cain, Swarupa Kulkarni, Bharti Shah, Janardhana Vemula, Gholamreza Rahmanzadeh, Birk Poller
Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator. Drug metabolism and disposition: the biological fate of chemicals 49 (5) (2021)